参考文献：

[1] Yung T K, Chan K C, Mok T S, *et al*. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients[J]. Clin Cancer Res, 2009, 15(6): 2076－2084.

[2] Mitsudomi T, Morita S, Yatabe Y, *et al*. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial[J]. Lancet Oncol, 2010, 11(2): 121－128.

[3] Fukuoka M, Wu Y L, Thongprasert S, *et al*. Biomarker analyses and final overall survival results from a phase Ⅲ, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)[J]. J Clin Oncol, 2011, 29(21): 2866－2874.

[4] Inoue A, Kobayashi K, Maemondo M, *et al*. A randomized phase Ⅲ study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study[J]. Eur J Cancer Suppl, 2009, 7(3): 6.

[5] Zhu C Q, da-Cunha-Santos G, Ding K, *et al*. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR. 21[J]. J Clin Oncol, 2008, 26(26): 4268－4275.

[6] Sholl L M, Xiao Y, Joshi V, *et al*. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry[J]. Am J Clin Pathol, 2010, 133(6): 922－934.

[7] Oremek G M, Sauer-Eppel H, Bruzdziak T H. Value of tumour and inflammatory markers in lung cancer[J]. Anticancer Res, 2007, 27(4A): 1911－1915.

[8] 刘杰，成媛，贾永旭，等. 血清CEA水平与EGFR-TKI治疗晚期非小细胞肺癌疗效及预后分析[J]. 第三军医大学学报，2011，33(7)：728－731.

[9] Okamoto T, Nakamura T, Ikeda J, *et al*. Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer[J]. Eur J Cancer, 2005, 41(9): 1286－1290.

[10] Kappers I, Vollebergh M A, van-Tinteren H, *et al*. Soluble epidermal growth factor receptor (sEGFR) and carcinoembryonic antigen (CEA) concentration in patients with non-small cell lung cancer: correlation with survival after erlotinib and gefitinib treatment[J]. Ecancermedicalscience, 2010, 4: 178.

[11] Barlesi F, Tchouhadjian C, Doddoli C, *et al*. CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy[J]. Br J Cancer, 2005, 92(1): 13－14.

[12] 邓丽平，董文，杜艳萍，等. 支气管肺泡灌洗液和血清肿瘤标志物联合检测在肺癌诊断中的价值[J]. 第三军医大学学报，2008，30(1)：78－80.

[13] Lee J H, Chang J H. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer[J]. Chest, 2005, 128(4): 2298－2303.

[14] Benchimol S, Fuks A, Jothy S, *et al*. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule[J]. Cell, 1989, 57(2): 327－334.

[15] Ordonez C, Screaton R A, Ilantzis C, *et al*. Human carcinoembryonic antigen functions as a general inhibitor of anoikis[J]. Cancer Res, 2000, 60(13): 3419－3424.

[16] Screaton R A, Penn L Z, Stanners C P. Carcinoembryonic antigen, a human tumor marker, cooperates with Myc and Bcl-2 in cellular transformation[J]. J Cell Biol, 1997, 137(4): 939－952.

[17] Shoji F, Yoshino I, Yano T, *et al*. Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas[J]. Cancer, 2007, 110(12): 2793－2798.

[18] Concannon J P, Dalbow M H, Hodgson S E, *et al*. Prognostic value of preoperative carcinoembryonic antigen (CEA) plasma levels in patients with bronchogenic carcinoma[J]. Cancer, 1978, 42(3 Suppl): 1477－1483.

[19] Kris M G, Natale R B, Herbst R S, *et al*. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial[J]. JAMA, 2003, 290(16): 2149－2158.

[20] Thatcher N, Chang A, Parikh P, *et al*. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)[J]. Lancet, 2005, 366(9496): 1527－1537.

[21] Akerley W, Boucher K M, Bentz J S, *et al*. A phase Ⅱ study of erlotinib as initial treatment for patients with stage ⅢB-Ⅳ non-small cell lung cancer[J]. J Thorac Oncol, 2009, 4(2): 214－219.

（收稿：2012-05-11；修回：2012-07-25）

（编辑 王 红）

参考文献中英文作者名的著录方法

医学期刊的论文中，引用英文文献的比例很高，但有不少作者将英、美人的姓名搞错，以至用光盘核对时出现错姓、错名或姓名全错。英、美人姓名的习惯写法是：名-名-姓，“名”可以有1个、2个或3个，但“姓”只有1个。因此，从书籍或期刊中的姓名转录到文献时，要将次序调整为姓-名-名。姓是不可以简写的；“名”可以缩写，用第一个字母大写，不用缩写点。数据库在著录作者姓名时，已经调整为姓-名-名，可照录。

例如：John Quincy Public 写为 Public J Q。

本刊编辑部